Autologous Mesenchymal Stromal Cells for Multiple Sclerosis

Relapsing-Remitting Multiple Sclerosis Clinical Trial

— EMMES  

Official title:

Treatment of Autologous Mesenchymal Stem Cells Derived From Bone Marrow as a Potential Therapeutic Strategy for the Treatment of Multiple Sclerosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02495766
• Other study ID #: XCEL-MS-02
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: May 11, 2015
• Est. completion date: November 15, 2018

Study information

• Verified date: January 2020
• Source: Banc de Sang i Teixits
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study evaluates the effect of cryopreserved autologous adult bone-marrow mesenchymal stromal cells (BM-MSC) in patients with active multiple sclerosis, compared to placebo.

Patients will be allocated to one of the 2 treatment arms (BM-MSC or placebo)and at month 6, the treatment will be crossed to receive the other product. The objective is to assess the safety of a single infusion BM-MSC, and to explore its efficacy in these patients.

Patients will be evaluated at month 12 and will be followed-up for a total of 3 years.

Description:

To date, there is no effective therapy to cure multiple sclerosis (MS). Immunomodulatory therapies are useful in reducing the frequency of inflammatory processes (relapses) but don't delay significantly the progression of the disease, prevent long term disability or induce the repair of damaged tissue. This proposal contemplates the use of adult autologous bone marrow mesenchymal stromal cells (BM-MSC) as an alternative therapeutic strategy to treat patients with active MS. This is a randomized, double blind, crossover clinical trial in which 8 patients with active forms of MS and moderate disability will enter the trial with the primary objective of assessing the safety and tolerability of a single intravenous infusion of BM-MSC. Secondary objectives are to assess the efficacy by gadolinium enhancing lesions though magnetic resonance imaging, neurophysiological effects and immunological effects. Once randomized, patients will undergo BM extraction and once confirmed the availability of the needed dose, they will be randomized to one of the 2 treatment arms (BM-MSC named XCEL-MC-ALPHA, or placebo). XCEL-MC-ALPHA will be cryopreserved for all patients regardless the allocated arm. At month 6, the treatment will be crossed. Patients will be evaluated at month 12 and will be followed-up for a total of 3 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 8
• Est. completion date: November 15, 2018
• Est. primary completion date: November 27, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Patients between 18 and 60 years of age

• Patients with MS

• Relapsing-remitting or secondary progressive MS

• Patients to whom are not indicated or are not in a position to initiate treatment with disease-modifying drugs

• Expanded Disability Status Scale (EDDS) score <6.5

• Nine T2 lesions at least

• Active multiple sclerosis as defined either by 1 outbreak in the last year or at least one Gadolinium-enhancing lesion in the last 6 months

• Signed informed consent form

Exclusion Criteria:

• Interferon beta or glatiramer acetate 3 months prior the screening

• Natalizumab or fingolimod in the 6 months prior the screening

• Mitoxantrone, cyclophosphamide or other immunosuppressive therapy at any time

• Has received an experimental treatment within 3 months prior the screening

• MS outbreak within the 4 weeks prior the randomization

• Serum creatinine> 2.0 mg/dl

• Infectious disease active or uncontrolled

• Fertile patients who are not using a suitable method of contraception

• Pregnant or lactating woman

• Immunodeficiency

• Positive serology to HIV, Hepatitis B, Hepatitis C or syphilis

Related Conditions & MeSH terms

• Multiple Sclerosis
• Multiple Sclerosis, Chronic Progressive
• Multiple Sclerosis, Relapsing-Remitting
• Relapsing-Remitting Multiple Sclerosis
• Sclerosis
• Secondary Progressive Multiple Sclerosis

Intervention

Drug:
• XCEL-MC-ALPHA
Single infusion
• Placebo
Single infusion

Locations

Country	Name	City	State
Spain	Hospital Vall Hebron	Barcelona

Sponsors (2)

Lead Sponsor	Collaborator
Banc de Sang i Teixits	Vall d'Hebron Research Institute (VHIR)

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse events	Safety profile	12 months
Secondary	Cumulative number of MRI Gd-enhancing lesions	Imaging procedure	12 months
Secondary	Multiple Sclerosis Outbreaks	Medical assessment	12 months
Secondary	Expanded Disability Status Scale (EDDS) score	Quantification of disability	12 months
Secondary	Cumulative number of lesions visualized on T2 sequence	Imaging procedure	12 months

External Links

•   Blood and Tissue Bank of Catalonia
•   Multiple Sclerosis center of Catalonia
•   Vall d'Hebron Research Institute